MeiraGTx (MGTX) Competitors

MeiraGTx (NASDAQ:MGTX) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

Do analysts rate MGTX or AMPH?

MeiraGTx currently has a consensus target price of $23.50, indicating a potential upside of 291.01%. Amphastar Pharmaceuticals has a consensus target price of $60.33, indicating a potential upside of 63.15%. Given MeiraGTx's stronger consensus rating and higher possible upside, equities analysts clearly believe MeiraGTx is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Amphastar Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

Which has better valuation & earnings, MGTX or AMPH?

Amphastar Pharmaceuticals has higher revenue and earnings than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$13.93M	33.72	-$84.03M	-$1.21	-4.97
Amphastar Pharmaceuticals	$723.55M	2.46	$137.54M	$3.00	12.33

Do institutionals & insiders believe in MGTX or AMPH?

67.5% of MeiraGTx shares are held by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. 8.4% of MeiraGTx shares are held by insiders. Comparatively, 27.1% of Amphastar Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Is MGTX or AMPH more profitable?

Amphastar Pharmaceuticals has a net margin of 21.80% compared to MeiraGTx's net margin of -633.05%. Amphastar Pharmaceuticals' return on equity of 26.44% beat MeiraGTx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	-633.05%	-146.38%	-53.05%
Amphastar Pharmaceuticals	21.80%	26.44%	11.89%

Does the media favor MGTX or AMPH?

In the previous week, Amphastar Pharmaceuticals had 5 more articles in the media than MeiraGTx. MarketBeat recorded 7 mentions for Amphastar Pharmaceuticals and 2 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 1.29 beat Amphastar Pharmaceuticals' score of 1.05 indicating that MeiraGTx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MeiraGTx	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amphastar Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk & volatility, MGTX or AMPH?

MeiraGTx has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500. Comparatively, Amphastar Pharmaceuticals has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500.

Does the MarketBeat Community favor MGTX or AMPH?

Amphastar Pharmaceuticals received 201 more outperform votes than MeiraGTx when rated by MarketBeat users. However, 71.54% of users gave MeiraGTx an outperform vote while only 66.22% of users gave Amphastar Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
MeiraGTx	Outperform Votes 191 71.54%	Underperform Votes 76 28.46%
Amphastar Pharmaceuticals	Outperform Votes 392 66.22%	Underperform Votes 200 33.78%

Summary

Amphastar Pharmaceuticals beats MeiraGTx on 10 of the 17 factors compared between the two stocks.